Evidence map›Paper›PMID 42588601›Full record

ArticleCancers2026

Molecular Characterization of PARP Inhibitor Response Reveals Co-Targeting Strategies in Advanced Prostate Cancer.

Bryan Correa Gonzalez, Akshaya Karthikeyan, Love A Moore, Anamitra Bhaumik, Ethan Sandoval, Marion Hardy, Ryan R Davis, Neelu Batra, Christopher A Lucchesi, Allen C Gao and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Bryan Correa GonzalezDepartment of Urologic Surgery, University of California, Davis, Sacramento, CA 95817, USA.
Akshaya KarthikeyanDepartment of Urologic Surgery, University of California, Davis, Sacramento, CA 95817, USA.
Love A MooreDepartment of Urologic Surgery, University of California, Davis, Sacramento, CA 95817, USA.
Anamitra BhaumikDepartment of Urologic Surgery, University of California, Davis, Sacramento, CA 95817, USA.
Ethan SandovalDepartment of Urologic Surgery, University of California, Davis, Sacramento, CA 95817, USA.
Marion HardyDepartment of Molecular and Cellular Biology, University of California, Davis, Davis, CA 95616, USA.ORCID 0009-0002-5190-0722
Ryan R DavisComprehensive Cancer Center, University of California, Davis, Sacramento, CA 95817, USA.ORCID 0000-0001-7439-6683
Neelu BatraDepartment of Urologic Surgery, University of California, Davis, Sacramento, CA 95817, USA.
Christopher A LucchesiDepartment of Urologic Surgery, University of California, Davis, Sacramento, CA 95817, USA.ORCID 0000-0001-8767-7003
Allen C GaoDepartment of Urologic Surgery, University of California, Davis, Sacramento, CA 95817, USA.
Hong LiComprehensive Cancer Center, University of California, Davis, Sacramento, CA 95817, USA.
John D McPhersonComprehensive Cancer Center, University of California, Davis, Sacramento, CA 95817, USA.
Marc Dall'EraDepartment of Urologic Surgery, University of California, Davis, Sacramento, CA 95817, USA.
Alan P LombardDepartment of Urologic Surgery, University of California, Davis, Sacramento, CA 95817, USA.

Funding

Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI KC KENT LLOYD · 2002 to 2026
$84.9M
The UC Davis enhanced Molecular, Cellular, and Developmental Biology Training ProgramT32GM153586 · NIGMS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Frederic Louis Chedin, ELVA D DIAZ · 2024 to 2026
$2.3M
Defining PARP Inhibitor Response and Resistance in Prostate CancerK01CA262351 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI LOMBARD, ALAN · 2021 to 2025
$833k
NCI NIH HHS 1K01CA262351-01NCI NIH HHS K01 CA262351NCI NIH HHS P30 CA093373NCI NIH HHS P30CA093373NCI NIH HHS T32GM153586-01NIGMS NIH HHS T32 GM153586
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

ATMAZD1390epithelial–mesenchymal transition (EMT)etomoxirfatostatinfatty acid metabolismlartesertib (M4076)olaparibpoly (ADP-ribose) polymerase (PARP) inhibitor (PARPi)prostate cancertalazoparib

Identifiers

PMID42588601
PMCPMC13464659

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.